Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy

Emiliano Fabiani; Maria Teresa Voso; Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena

doi:10.2147/OTT.S59628

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy

Emiliano Fabiani, Maria Teresa Voso, Pellegrino Musto, Vittorio Simeon, Roberto Guariglia, Gabriella Bianchino, Vitina Grieco, Filomena Nozza, Francesco La Rocca, Gioacchino Marziano, Anna Vittoria Lalinga, Patrizia Scaravaglio, Cristina Mecucci, Giovanni D'Arena

Facoltà di Medicina e Chirurgia "A.Gemelli"

Risultato della ricerca: Contributo in rivista › Articolo in rivista

10 Citazioni (Scopus)

Abstract

The concomitant presence of del(5q) and JAK2(V617F) mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing - from a clinical, pathological, and biological point of view - for at least some of these patients as a potential distinct entity is discussed.

Lingua originale	English
pagine (da-a)	1043-1050
Numero di pagine	8
Rivista	Onco Targets Ther
DOI	https://doi.org/10.2147/OTT.S59628
Stato di pubblicazione	Pubblicato - 2014

Keywords

JAK2
del(5q)

Accesso al documento

10.2147/OTT.S59628

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint Entra nei temi di ricerca di 'Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy'. Insieme formano una fingerprint unica.

Cita questo

Fabiani, E., Voso, M. T., Musto, P., Simeon, V., Guariglia, R., Bianchino, G., Grieco, V., Nozza, F., La Rocca, F., Marziano, G., Lalinga, A. V., Scaravaglio, P., Mecucci, C., & D'Arena, G. (2014). Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. Onco Targets Ther, 1043-1050. https://doi.org/10.2147/OTT.S59628

Fabiani, Emiliano ; Voso, Maria Teresa ; Musto, Pellegrino ; Simeon, Vittorio ; Guariglia, Roberto ; Bianchino, Gabriella ; Grieco, Vitina ; Nozza, Filomena ; La Rocca, Francesco ; Marziano, Gioacchino ; Lalinga, Anna Vittoria ; Scaravaglio, Patrizia ; Mecucci, Cristina ; D'Arena, Giovanni. / Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. In: Onco Targets Ther. 2014 ; pagg. 1043-1050.

@article{4f125ab1977543958e476d5450c54df1,

title = "Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy",

abstract = "The concomitant presence of del(5q) and JAK2(V617F) mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing - from a clinical, pathological, and biological point of view - for at least some of these patients as a potential distinct entity is discussed.",

keywords = "JAK2, del(5q), JAK2, del(5q)",

author = "Emiliano Fabiani and Voso, {Maria Teresa} and Pellegrino Musto and Vittorio Simeon and Roberto Guariglia and Gabriella Bianchino and Vitina Grieco and Filomena Nozza and {La Rocca}, Francesco and Gioacchino Marziano and Lalinga, {Anna Vittoria} and Patrizia Scaravaglio and Cristina Mecucci and Giovanni D'Arena",

year = "2014",

doi = "10.2147/OTT.S59628",

language = "English",

pages = "1043--1050",

journal = "Onco Targets Ther",

}

Fabiani, E, Voso, MT, Musto, P, Simeon, V, Guariglia, R, Bianchino, G, Grieco, V, Nozza, F, La Rocca, F, Marziano, G, Lalinga, AV, Scaravaglio, P, Mecucci, C & D'Arena, G 2014, 'Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy', Onco Targets Ther, pagg. 1043-1050. https://doi.org/10.2147/OTT.S59628

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. / Fabiani, Emiliano; Voso, Maria Teresa; Musto, Pellegrino; Simeon, Vittorio; Guariglia, Roberto; Bianchino, Gabriella; Grieco, Vitina; Nozza, Filomena; La Rocca, Francesco; Marziano, Gioacchino; Lalinga, Anna Vittoria; Scaravaglio, Patrizia; Mecucci, Cristina; D'Arena, Giovanni.

In: Onco Targets Ther, 2014, pag. 1043-1050.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy

AU - Fabiani, Emiliano

AU - Voso, Maria Teresa

AU - Musto, Pellegrino

AU - Simeon, Vittorio

AU - Guariglia, Roberto

AU - Bianchino, Gabriella

AU - Grieco, Vitina

AU - Nozza, Filomena

AU - La Rocca, Francesco

AU - Marziano, Gioacchino

AU - Lalinga, Anna Vittoria

AU - Scaravaglio, Patrizia

AU - Mecucci, Cristina

AU - D'Arena, Giovanni

PY - 2014

Y1 - 2014

N2 - The concomitant presence of del(5q) and JAK2(V617F) mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing - from a clinical, pathological, and biological point of view - for at least some of these patients as a potential distinct entity is discussed.

AB - The concomitant presence of del(5q) and JAK2(V617F) mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing - from a clinical, pathological, and biological point of view - for at least some of these patients as a potential distinct entity is discussed.

KW - JAK2

KW - del(5q)

KW - JAK2

KW - del(5q)

UR - http://hdl.handle.net/10807/60305

U2 - 10.2147/OTT.S59628

DO - 10.2147/OTT.S59628

M3 - Article

SP - 1043

EP - 1050

JO - Onco Targets Ther

JF - Onco Targets Ther

ER -